SERPINA1 and chronic obstructive pulmonary disease: The need to assess the risks for patients heterozygous for SERPINA1 mutations has also been raised [34], even though their antitrypsin levels may not fall below the normal range and they may not develop fulminant COPD as homozygotes do.